핵의학적 관점에서 본 미국갑상선학회 진료권고안

키워드

참고문헌 (79)

1. Singer PA, "Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association", Arch Intern Med, 156(19), pp.2165~2172 (1996)
2. Cooper DS, "Management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 16(2), pp.109~142 (2006)
3. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
4. Yi KH, "Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer", J Korean Thyroid Assoc, 3(2), pp.65~96 (2010)
5. 김원배, "갑상선암 방사성요오드 치료에 관한 환자 안내서- 제 1 판(2012) -", International Journal of Thyroidology, 6(1), pp.12~25 (2013), 대한갑상선학회
6. Tuttle RM, "Follow up approaches in thyroid cancer:a risk adapted paradigm", Endocrinol Metab Clin North Am, 37(2), pp.419~435, ix-x (2008)
7. Tuttle RM, "Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system", Thyroid, 20(12), pp.1341~1349 (2010)
8. Vaisman F, "Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer", Clin Endocrinol (Oxf), 75(1), pp.112~119 (2011)
9. Jonklaas J, "Outcomes of patients with differentiated thyroid carcinoma following initial therapy", Thyroid, 16(12), pp.1229~1242 (2006)
10. Jonklaas J, "Radioiodine therapy in patients with stage I differentiated thyroid cancer", Thyroid, 20(12), pp.1423~1424 (2010)
11. Sacks W, "The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008", Thyroid, 20(11), pp.1235~1245 (2010)
12. Sawka AM, "An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer", Endocrinol Metab Clin North Am, 37(2), pp.457~480 (2008)
13. Ross DS, "Recurrence after treatment of micropapillary thyroid cancer", Thyroid, 19(10), pp.1043~1048 (2009)
14. Kim HJ, "Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma", Clin Endocrinol (Oxf), 78(4), pp.614~620 (2013)
15. Baudin E, "Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience", Cancer, 83(3), pp.553~559 (1998)
16. Creach KM, "Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma", ISRN Endocrinol, 2012, pp.816386~ (2012)
17. Lin HW, "Survival impact of treatment options for papillary microcarcinoma of the thyroid", Laryngoscope, 119(10), pp.1983~1987 (2009)
18. Kuo EJ, "Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients", Surgery, 154(6), pp.1246~1254 (2013)
19. Mallick U, "Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo", Clin Oncol (R Coll Radiol), 24(3), pp.159~161 (2012)
20. Kazaure HS, "Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients", Ann Surg Oncol, 19(6), pp.1874~1880 (2012)
21. Kazaure HS, "Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival", Cancer, 118(13), pp.3260~3267 (2012)
22. Chow SM, "Local and regional control in patients with papillary thyroid carcinoma:specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition", Endocr Relat Cancer, 13(4), pp.1159~1172 (2006)
23. Podnos YD, "Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope", J Surg Oncol, 96(1), pp.3~7 (2007)
24. Lee J, "Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroidstimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma", Thyroid, 20(2), pp.173~179 (2010)
25. Robbins RJ, "Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine", Thyroid, 16(11), pp.1121~1130 (2006)
26. Chianelli M, "Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients", Eur J Endocrinol, 160(3), pp.431~436 (2009)
27. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
28. Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study", J Clin Endocrinol Metab, 91(3), pp.926~932 (2006)
29. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
30. Taieb D, "Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study", Clin Endocrinol (Oxf), 71(1), pp.115~123 (2009)
31. Emmanouilidis N, "Surgery and radioablation therapy combined:introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH", Eur J Endocrinol, 161(5), pp.763~769 (2009)
32. Tu J, "Recombinant human thyrotropin-aided versus thyroid hormone withdrawalaided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis", Radiother Oncol, 110(1), pp.25~30 (2014)
33. Elisei R, "Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal", J Clin Endocrinol Metab, 94(11), pp.4171~4179 (2009)
34. Emmanouilidis N, "Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism", Int J Endocrinol, 2013, pp.769473~ (2013)
35. Hugo J, "Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence", Thyroid, 22(10), pp.1007~1015 (2012)
36. Rosario PW, "Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine", Thyroid, 22(3), pp.332~333 (2012)
37. Pitoia F, "Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer", J Thyroid Res, 2012, pp.481568~ (2012)
38. Bartenstein P, "High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal", Thyroid, 24(3), pp.480~487 (2014)
39. Tala H, "Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH", J Clin Endocrinol Metab, 96(7), pp.2105~2111 (2011)
40. Klubo-Gwiezdzinska J, "Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin", Thyroid, 22(3), pp.310~317 (2012)
41. Maenpaa HO, "Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study", PLoS One, 3(4), pp.e1885~ (2008)
42. Pilli T, "A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer", J Clin Endocrinol Metab, 92(9), pp.3542~3546 (2007)
43. Zaman M, "A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers", J Pak Med Assoc, 56(8), pp.353~356 (2006)
44. Kukulska A, "Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi", Thyroid Res, 3(1), pp.9~ (2010)
45. Fang Y, "Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network metaanalyses", J Endocrinol Invest, 36(10), pp.896~902 (2013)
46. Ma C, "rhTSH-aided lowactivity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis", Nucl Med Commun, 34(12), pp.1150~1156 (2013)
47. Cheng W, "Lowor high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis", J Clin Endocrinol Metab, 98(4), pp.1353~1360 (2013)
48. Valachis A, "High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis", Acta Oncol, 52(6), pp.1055~1061 (2013)
49. Castagna MG, "Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients", Eur J Endocrinol, 169(1), pp.23~29 (2013)
50. Han JM, "Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension", Thyroid, 24(5), pp.820~825 (2014)
51. Kruijff S, "Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma", Surgery, 154(6), pp.1337~1345 (2013)
52. Sabra MM, "Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases", Thyroid, 24(7), pp.1088~1095 (2014)
53. Schlumberger M, "Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients", Nat Clin Pract Endocrinol Metab, 3(3), pp.260~269 (2007)
54. Kulkarni K, "The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer", Thyroid, 16(10), pp.1019~1023 (2006)
55. Tuttle RM, "Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer", J Nucl Med, 47(10), pp.1587~1591 (2006)
56. Hebestreit H, "Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl", Eur J Nucl Med Mol Imaging, 38(9), pp.1683~1690 (2011)
57. Ilgan S, "Iodine-131 treatment and high-resolution CT:results in patients with lung metastases from differentiated thyroid carcinoma", Eur J Nucl Med Mol Imaging, 31(6), pp.825~830 (2004)
58. Hod N, "Differentiated thyroid carcinoma in children and young adults:evaluation of response to treatment", Clin Nucl Med, 30(6), pp.387~390 (2005)
59. Schlumberger M, "Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma", J Nucl Med, 37(4), pp.598~605 (1996)
60. Schlumberger M, "Definition and management of radioactive iodine-refractory differentiated thyroid cancer", Lancet Diabetes Endocrinol, 2(5), pp.356~358 (2014)
61. Deandreis D, "Is (18)F-fluorodeoxyglucose-PET", CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology?, 2012, pp.22(2), 165~172
62. -2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature, "Cancer", 2011, 4582~4594
63. Wang N, "Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature", J Otolaryngol Head Neck Surg, 42, pp.38~ (2013)
64. Soelberg KK, "Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review", Thyroid, 22(9), pp.918~925 (2012)
65. Chen W, "Evaluation of thyroid FDG uptake incidentally identified on FDG-PET", CT imaging, 2009, pp.30(3), 240~244
66. Nishimori H, "Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake", Can J Surg, 54(2), pp.83~88 (2011)
67. fluoro-2-deoxy-D-glucose-positron emission tomography scanning, "J Clin Endocrinol Metab", 2006, 498~505
68. Deandreis D, "Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?", Endocr Relat Cancer, 18(1), pp.159~169 (2011)
69. Ciappuccini R, "Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer", Eur J Endocrinol, 164(6), pp.961~969 (2011)
70. Salvatori M, "Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging", Nucl Med Commun, 34(9), pp.900~908 (2013)
71. Kohlfuerst S, "Posttherapeutic (131)I SPECTCT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen", Eur J Nucl Med Mol Imaging, 36(6), pp.886~893 (2009)
72. Chen L, "Incremental value of 131I SPECT", CT in the management of patients with differentiated thyroid carcinoma, 2008, pp.49(12), 1952~1957
73. Schmidt D, "Five months'follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT", CT at the first radioablation, 2010, pp.37(4), 699~705
74. Maruoka Y, "Incremental diagnostic value of SPECT", CT with 131I scintigraphy after radioiodine therapy in patients with welldifferentiated thyroid carcinoma, 2012, pp.265(3), 902~909
75. Grewal RK, "The effect of posttherapy 131I SPECT", CT on risk classification and management of patients with differentiated thyroid cancer, 2010, pp.51(9), 1361~1367
76. Aide N, "Clinical relevance of single-photon emission computed tomography", computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer, 2009, pp.94(6), 2075~2084
77. Schmidt D, "Impact of 131I SPECT", spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation, 2009, pp.50(1), 18~23
78. Jeong SY, "Clinical applications of SPECT", CT after first I-131 ablation in patients with differentiated thyroid cancer, 2014, pp.81(3), 445~451
79. Tharp K, "Impact of 131I-SPECT", CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma, 2004, pp.31(10), 1435~1442

관련 논문AI추천